Date: April 26, 2022 Administrative Circular: 2022:16

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

- **Doses and Schedule:**
  Footnote C has been revised to indicate clients requesting a shorter interval between
doses should be informed that this is not optimal for protection, but their request for an
earlier dose should be granted, without need for MHO approval.

- The **ADDENDUM:** Pooling residual vaccine from up to three vials to constitute an extra
dose has been removed. While this was an appropriate strategy at the implementation of
the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a
deviation from best practice.

Please remove page numbers: 1-7 dated April 13, 2022
Please add new page numbers: 1-6 dated April 26, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Pediatric)

- **Doses and Schedule:**
  Footnote C has been revised to indicate clients requesting a shorter interval between
doses should be informed that this is not optimal for protection, but their request for an
earlier dose should be granted, without need for MHO approval.

- The **ADDENDUM:** Pooling residual vaccine from up to three vials to constitute an extra
dose has been removed. While this was an appropriate strategy at the implementation of
the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a
deviation from best practice.

Please remove page numbers: 1-6 dated March 18, 2022
Please add new page numbers: 1-5 dated April 26, 2022
COVID-19 Vaccine SPIKEVAX™ (Moderna)

- Doses and Schedule:
  Footnote B has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-6 dated April 13, 2022
Please add new page numbers: 1-5 dated April 26, 2022

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-5 dated April 13, 2022
Please add new page numbers: 1-4 dated April 26, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-5 dated April 13, 2022
Please add new page numbers: 1-4 dated April 26, 2022

COVID-19 Vaccine Nuvaxovid™ (Novavax)

- Doses and Schedule:
  Footnote C has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.

Please remove page numbers: 1-3 dated April 13, 2022
Please add new page numbers: 1-3 dated April 26, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division